Atavistik Bio develops selective allosteric small-molecule therapeutics using its proprietary AMPS platform to treat conditions such as Hereditary Hemorrhagic Telangiectasia and myeloproliferative neoplasms.
atavistikbio.comPart of: Boston tech scene from Fundable